Skip to main content
Download PDF

Biomarkers of tissue remodelling are elevated in serum of COVID-19 patients who develop interstitial lung disease - an exploratory biomarker study

BMC Pulmonary Medicine volume 24, Article number: 331 (2024) Cite this article

Abstract

Background

Coronavirus disease 2019 (COVID-19) is a viral pneumonia that can result in serious respiratory illness. It is associated with extensive systemic inflammation, changes to the lung extracellular matrix, and long-term lung impairment such as interstitial lung disease (ILD). In this study, the aim was to investigate whether tissue remodelling, wound healing, and neutrophil activity is altered in patients with COVID-19 and how these relate to the development of post-COVID ILD.

Method

Serum samples were collected from 63 patients three months after discharge as part of the Research Evaluation Alongside Clinical Treatment study in COVID-19 (REACT COVID-19), 10 of whom developed ILD, and 16 healthy controls. Samples were quantified using neo-epitope specific biomarkers reflecting tissue stiffness and formation (PC3X, PRO-C3, and PRO-C6), tissue degradation (C1M, C3M, and C6M), wound healing (PRO-FIB and X-FIB), and neutrophil activity (CPa9-HNE and ELP-3).

Results

Mean serum levels of PC3X (p < 0.0001), PRO-C3 (p = 0.002), C3M (p = 0.009), PRO-FIB (p < 0.0001), CPa9-HNE (p < 0.0001), and ELP-3 (p < 0.0001) were significantly elevated in patients with COVID-19 compared to healthy controls. Moreover, PC3X (p = 0.023) and PRO-C3 (p = 0.032) were significantly elevated in post-COVID ILD as compared to COVID-19.

Conclusion

Serological biomarkers reflecting type III collagen remodelling, clot formation, and neutrophil activity were significantly elevated in COVID-19 and type III collagen formation markers were further elevated in post-COVID ILD. The findings suggest an increased type III collagen remodelling in COVID-19 and warrants further investigations to assess the potential of tissue remodelling biomarkers as a tool to identify COVID-19 patients at high risk of developing ILD.

Peer Review reports

Introduction

Coronavirus disease 2019 (COVID-19) is a severe viral pneumonia that was estimated to be one of the leading causes of death in 2020 and 2021 with a global death count of 18.2 million [1]. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an enveloped, single-stranded RNA virus which transmits through droplets and primarily infects the respiratory tract [2, 3]. Emerging data suggest multi-organ involvement where lung damage has been suggested as the most common serious manifestation [3, 4]. Long-term lung impairment may develop after clearance of the virus and in particular interstitial lung disease (ILD), often referred to as post-COVID ILD.

ILD is an umbrella term that refers to a wide range of inflammatory and fibrotic pulmonary diseases. Pulmonary fibrosis is characterized by a dysregulated extracellular matrix (ECM) remodelling, resulting in an excessive deposition of ECM components. The ECM is a highly dynamic, three-dimensional network present in all tissues, consisting of noncellular components such as elastin and collagens [5]. Collagens, specifically type I, III, and VI, constitute a major part of the lung tissue and contribute to the organ’s overarching architecture [6]. Type III collagen is the main protein produced during early tissue remodelling, followed by type I collagen [7, 8]. As the tissue remodels, ECM proteins are degraded and synthesized, resulting in the release of peptide fragments (neoepitopes) into circulation. In circulation, the fragments can be measured serologically to assess tissue remodelling. This has been done previously and shown to associate with disease severity, progression, and mortality in patients with pulmonary fibrosis [9,10,11]. Additionally, neoepitopes that has a bioactive function, called matrikines, have also been suggested to drive inflammation [12].

The lungs of COVID-19 patients have shown to be significantly altered with features such as diffuse alveolar damage, microthrombi in the interalveolar septa, and fibrotic changes [13,14,15]. Radiological and physiological lung abnormalities has been found in 71% of COVID-19 survivors three months after recovery [16] and in one third of patients abnormalities in pulmonary function was persistent at 12 months after discharge and radiological changes did not resolve in 24% of patients [17]. An interim analysis in the UK Interstitial Lung Disease Consortium (UKILD) post-COVID-19 study, estimated that the risk of residual lung abnormalities in patients with severe COVID-19 was up to 11% [18]. Infection with other coronaviruses such as middle east respiratory syndrome coronavirus (MERS-CoV) showed fibrotic abnormalities in one third of patients at 32 to 230 days follow up [19] and a long-term longitudinal study of SARS-CoV-infected health-care workers showed that 5% of the patients had residual interstitial fibrosis after 15 years [20].

Neutrophils have shown to play a prominent role in COVID-19 and increased blood neutrophil count, neutrophil-to-lymphocyte ratio, and elevated serum levels of neutrophil related cytokines have been observed in patients with severe disease [21,22,23,24]. Additionally, increased concentration of neutrophil extracellular traps (NETs) has been observed in tracheal aspirate, plasma, airways, and in the alveoli of SARS-CoV-2 infected patients [25,26,27]. In excess, NETs can contribute to a cytokine storm which may further exacerbate disease severity, progress into acute respiratory distress syndrome (ARDS), and lead to multiorgan failure and death [28, 29]. Indeed, elevated cytokine levels has been observed in COVID-19 patients and many are believed to have died from the response [30, 31]. The rapid increase in cytokines attract new inflammatory cells, resulting in an excessive infiltration of inflammatory cells in the lung tissue, further contributing to lung injury.

To explore aspects of the COVID-19 and post-COVID ILD pathophysiology in the non-acute phase, this study aimed to investigate the tissue remodelling, wound healing, and neutrophil activity using serological biomarkers.

Materials and methods

Study design and patients

Data and serum samples were collected as part of the Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19) study (20/HRA/2986) at University Hospital Southampton (UHS) NHS Foundation Trust (Southampton, United Kingdom) and the Southampton Research Biorepository (17/NW/0362) [32]. Data were collected from patients admitted to UHS with COVID-19 infection between May 2020 and January 2021. The patients were diagnosed at the point of attendance to the Emergency Department and admitted based on severity of symptoms and oxygen requirement.

Three months after in-hospital treatment and subsequent discharge, patients were followed-up for symptom re-assessment and serum samples were collected for research purposes. C-reactive protein (CRP), neutrophil count, and lymphocyte count were collected as part of clinical care. All patients provided informed written consent. Depending on patient-reported symptoms, further investigations such as pulmonary function tests and computed tomography (CT) of the thorax were undertaken. Demographic and clinical information was gathered from the UHS electronic clinical recording systems. Presence of ILD was determined by thoracic radiologists as part of clinical care and was defined as the presence of ground glass opacities, reticulations, or fibrosis within the lung parenchyma. As diagnosis was made during routine clinical management, the degree of ILD was not formally scored. Data on forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) was registered for the post-COVID ILD patients. Comorbidities were registered for all patients and divided into five categories: diabetes, hypertension, obesity, respiratory diseases, or none. The respiratory diseases group included asthma, chronic obstructive pulmonary disease (COPD), and emphysema. Lastly, 16 unmatched healthy controls were obtained from a commercial vendor BioIVT (West Sussex, UK) and included in the analysis for comparison.

Biomarker measurements

Serum samples collected from patients and healthy controls were stored at -80 °C until analysis. A panel of neo-epitope specific biomarkers were quantified in the collected serum samples, see Table 1. The biomarkers reflect type III collagen crosslinking (nordicPC3X™ [33]), type III and VI collagen formation (nordicPRO-C3™ [34] and nordicPRO-C6™ [35]), type I, III, and VI collagen degradation by matrix metalloproteinases (nordicC1M™ [36], nordicC3M™, [37] and nordicC6M™ [38]), calprotectin degradation by neutrophil elastase (nordicCPa9-HNE™ [39]), elastin degradation by proteinase 3 (nordicELP-3™ [40]), fibrin formation (nordicPRO-FIB™ [41]), and fibrin crosslinking and degradation (nordicX-FIB™ [42]). Biomarkers were quantified by enzyme-linked immunosorbent assays (ELISAs) utilizing neo-epitope specific monoclonal antibodies. In brief, streptavidin coated 96-well plates were incubated with appropriate biotinylated synthetic peptide or antibody for 30 min at 20 °C. Subsequently, 20 µL calibrator peptide, control, or serum sample was added to appropriate wells, followed by 100 µL monoclonal antibody targeting the specific sequence of interest or 80 µL buffer. The plates were incubated for 1–20 h at 4–20 °C according to the manufacturer’s instructions and where applicable followed by incubation with 100 µL secondary antibody for 1 h at 20 °C. Lastly, 100 µL TMB were added to the wells and incubated for 15 min before addition of 100 µL stopping solution, and plates were read spectrophotometrically, or 100 µL chemiluminescence substrate was added to the wells and incubated for 3 min before reading the relative light units using SpectraMax i3x. Biomarker levels were determined from the calibration curve. All incubation steps were performed with shaking at 300 rpm and followed by five washing steps. All samples were measured in duplicate with an acceptance criterion of coefficient of variance percentage (CV%) ≤ 20. Samples below the lower limit or above the upper limit of the measurement range (LLMR and ULMR) were given the value of the LLMR or ULMR for the respective assay.

Table 1 Biomarker panel
Full size table

Statistical analyses

Statistical analyses were performed using GraphPad Prism (version 9.1.2). Data were examined for normality using D’Agostino-Pearson omnibus test and Mann-Whitney test was used when comparing two groups. To investigate for correlations, Spearman’s rank correlation test was applied. Fisher’s exact test or Chi-square test was used to investigate contingency tables. Adjustments were done using a linear regression model in R (version 4.2.2). Data are shown as median with interquartile range, where differences were considered statistically significant if p < 0.05. Asterisks indicate the following: * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001, and ns = not significant.

Results

Patient characteristics

The 16 healthy controls were predominantly male (75%) and had a mean age of 42 years (standard deviation (SD) 16), see Table 2. 56% of the controls were Caucasian and 44% were Black. 56% of the 63 COVID-19 patients were male with a mean age of 56 years (SD 14). The age was statistically different between the healthy controls and COVID-19 patients (p = 0.005). 88% of the COVID-19 patients were Caucasian and 12% were Asian. Additionally, 19% had diabetes, 26% had hypertension, 13% had obesity, 13% had respiratory diseases, and 44% of the patients had no comorbidities. 16% of the COVID-19 patients had more than one comorbidity.

Table 2 Demographics of healthy controls and patients with COVID-19
Full size table

In Table 3, demographics for patients with COVID-19 without ILD and COVID-19 with post-COVID ILD are shown. In short, 10 (16%) of the COVID-19 patients developed post-COVID ILD. The post-COVID ILD patients had nearly the same distribution of males as those without ILD (60% vs. 56%) and a slightly higher mean age (62 years vs. 55 years). There was no statistical difference in age, sex, ethnicity, comorbidities, CRP, neutrophil count, or lymphocyte count between the two groups. The FVC and DLCO was registered for 9 of the 10 post-COVID ILD patients, and they had a mean FVC of 82.7% (SD 24.3) and mean DLCO of 89.4% (SD 21.7) of predicted.

Table 3 Demographics of patients with COVID-19 no ILD and post-COVID ILD
Full size table

Tissue remodelling biomarkers are elevated in COVID-19 and post-COVID ILD

Biomarker data on healthy controls and patients with COVID-19 are summarized in Table 4. Patients with COVID-19 had significantly elevated serum levels of type III collagen formation biomarkers PC3X and PRO-C3 (p < 0.0001 and p = 0.002) when compared to healthy controls, see Fig. 1A and B. Type VI collagen formation biomarker PRO-C6 showed no significant difference between the two groups (p = 0.174, Fig. 1C).

Fig. 1
figure 1

ECM formation and degradation biomarkers in patients with COVID-19. Note Healthy controls: n = 16, COVID-19: n = 63. Data were analysed with Mann Whitney test and shown as median with interquartile range

Full size image

The levels of type III collagen degradation biomarker C3M were significantly elevated in serum from patients with COVID-19 (p = 0.009), but type I and VI collagen degradation biomarkers C1M and C6M showed no significant difference in COVID-19 patients when compared to healthy controls (p = 0.107 and p = 0.084), see Fig. 1D, E and F.

The levels of wound healing biomarker PRO-FIB were significantly elevated in serum of patients with COVID-19 when compared to healthy controls (p < 0.0001) whereas X-FIB did not show any difference between the two groups (p = 0.525), see Fig. 2A and B.

Fig. 2
figure 2

Wound healing and neutrophil activity biomarkers in patients with COVID-19. Note Healthy controls: n = 16, COVID-19: n = 63. Data were analysed with Mann Whitney test and shown as median with interquartile range

Full size image

Neutrophil activity biomarkers CPa9-HNE and ELP-3 had significantly elevated serum levels in patients with COVID-19 when compared to healthy controls (both: p < 0.0001), see Fig. 2C and D. No correlation was found between neutrophil activity biomarkers and neutrophil count.

Table 4 Biomarker measurements in healthy controls and COVID-19
Full size table

Biomarker data on patients with COVID-19 without ILD and COVID-19 with post-COVID ILD are summarized in Table 5. Type III collagen formation biomarkers PC3X and PRO-C3 showed significantly elevated serum levels in post-COVID ILD patients as compared to COVID-19 without ILD (p = 0.023 and p = 0.032, respectively), see Fig. 3. None of the other biomarkers showed significant differences between the two groups, though type VI collagen formation biomarker PRO-C6 was borderline significant with elevated serum levels in post-COVID ILD when compared to COVID-19 without ILD (p = 0.061).

Table 5 Biomarker measurements in COVID-19 without ILD and post-COVID ILD
Full size table
Fig. 3
figure 3

Type III collagen formation biomarkers in patients with COVID-19 and post-COVID ILD. Note COVID-19 without ILD: n = 53, post-COVID ILD: n = 10. Data were analysed with Mann Whitney test and shown as median with interquartile range

Full size image

As the healthy controls and COVID-19 patients were non-matched, we investigated the influence of age, gender, ethnicity, and comorbidities on the biomarkers. Apart from PC3X, PRO-C6, and C6M, none of the biomarkers were influenced by these potential confounding factors in neither of the groups (data not shown). PC3X was significantly elevated in obese COVID-19 patients compared to non-obese COVID-19 patients (mean 36.4 [IQR 22.1–87.2] vs. 18.9 [IQR 12.7–31.9], p = 0.017). When excluding obese patients from the PC3X biomarker analysis no differences were observed compared to the original analysis (data not shown). Increasing PRO-C6 levels were associated with increasing age in both healthy controls and COVID-19 (correlation coefficient [r] = 0.329; p = 0.020 and r = 0.144; p = 0.002, respectively). When adjusting PRO-C6 for age, the results remained the same and there was no significant difference between the two groups (data not shown). Lastly, C6M levels were increased in Caucasians compared to Blacks in healthy controls (mean 17.3 [IQR 14.8–19.2] vs. 11.1 [IQR 9.2–13.8], p = 0.016). When comparing C6M levels in healthy controls and COVID-19 within Caucasian patients only, no differences were observed compared to the original analysis (data not shown).

Discussion

This study aimed to investigate different pathophysiological aspects of COVID-19 and post-COVID ILD in the non-acute phase using exploratory biomarkers reflecting tissue remodelling, wound healing, and neutrophil activity. A panel of biomarkers reflecting these different biological processes were measured and showed different serum level signatures in healthy controls, COVID-19, and post-COVID ILD.

Type III collagen remodelling is elevated in COVID-19

Following an acute injury to the lungs such as in COVID-19, the uncontrolled inflammatory response may lead to local and systemic tissue damage [43]. The tissue damage can be characterized by assessing the remodelling of various collagens, where type III collagen is one of the important fibrillar collagens that helps maintain the structure and function within various tissues [44]. PC3X, PRO-C3, and C3M are all biomarkers which measure different post-translational modifications leading to type III collagen remodelling. PC3X reflects ECM formation and tissue stiffness [33], PRO-C3 measures ECM formation, and C3M measures ECM degradation by matrix metalloproteinases. Both PC3X, PRO-C3 and C3M were shown to be significantly increased in serum of COVID-19 patients three months after discharge as compared to healthy controls. These findings align with Ackermann and colleagues who observed elevated PRO-C3 levels in plasma of severe COVID-19 patients when compared to no, mild, or moderate COVID-19, although no statistical significance was achieved in that study [45]. Changes in the remodelling of type III collagen have previously been associated with other diseases, such as liver and lung fibrosis [10, 11, 46]. These findings indicate an increased type III collagen remodelling in COVID-19 which could suggest similarities between the processes related to fibrotic diseases.

Clot formation was elevated in COVID-19

Upon tissue injury, a cascade of events is initiated to repair the structural and functional integrity of the wound, including clot formation and clot resolution. The wound healing biomarker PRO-FIB measures a protein fragment which is released when fibrinogen is converted into fibrin and the biomarker X-FIB measures the plasmin mediated degradation of crosslinked fibrin; thus, the biomarkers reflect two distinct processes of wound healing, namely the clot formation and the resolution of a stable clot. Elevated levels of PRO-FIB were found in serum of patients with COVID-19, indicating that there was active wound healing with higher rate of clot formation at the time of blood sampling, three months after discharge, when compared to controls. Serum levels of X-FIB were not different between healthy controls and patients with COVID-19, indicating that resolution of the stable clot had not yet started or that the clot had not yet had enough time to become stable and create crosslinks. Another known predictor of severity and mortality in patients with COVID-19 is D-dimer. D-dimer is a protein fragment of fibrinogen and fibrin degradation that is released when a blood clot dissolves and it has been shown to be elevated in blood of severe COVID-19 patients at baseline and at three months follow-up [47, 48]. The contradictory findings between the D-dimer fragment and X-FIB could be explained by the fact that X-FIB measures the level of degraded crosslinked fibrin and thus reflects stable clot resolution whereas D-dimer reflects total clot resolution. This could indicate that COVID-19 patients have an abnormal wound healing process with an accelerated clot formation and subsequent breakdown of newly formed clots.

Biomarkers of neutrophil activity are elevated in COVID-19

Previous studies have shown that severe COVID-19 patients have an increased blood neutrophil count, neutrophil-to-lymphocyte ratio, and elevated serum levels of neutrophil related cytokines, proposing an increased neutrophil activity [22,23,24, 27]. Thus, in this study, two neutrophil activity biomarkers, CPa9-HNE and ELP-3, were measured to investigate this biological process. CPa9-HNE reflects human neutrophil elastase mediated degradation of calprotectin and ELP-3 reflects proteinase 3 mediated degradation of elastin. Neutrophil elastase and proteinase 3 are both neutrophil serine proteinases which are released by neutrophils and play a part in the pathophysiology of various lung diseases [49]. Calprotectin is a protein mainly found within neutrophils, which gets released in the tissue together with neutrophil elastase when neutrophils initiate the process of NET formation [39]. Serum levels of CPa9-HNE and ELP-3 were significantly elevated in patients with COVID-19 as compared to healthy controls which indicate an increased neutrophil activity in patients with COVID-19 at three months after discharge. Neutrophil activity biomarkers did not correlate with neutrophil count, which was not surprising, as the biomarkers measure activity rather than the number of neutrophils. In other studies, calprotectin was found elevated in plasma of COVID-19 patients with severe disease as compared to those with mild [50] and neutrophil elastase was elevated in the blood of COVID-19 patients as compared to controls and associated with poor outcome and lung damage using CT score [51, 52]. Furthermore, the neutrophil activity in COVID-19 aligns with what has been seen in other lung diseases, such as COPD and ARDS, [53,54,55] and highlights the crucial function of neutrophil serine proteases and their possible pathological implications. The elevated serum levels of CPa9-HNE and ELP-3 align with these other studies and offer a tool to not only assess the neutrophil count, but neutrophil activity in patients with COVID-19.

Post-COVID ILD was associated with increased type III collagen formation

Patients who developed post-COVID ILD had significantly elevated levels of the type III collagen biomarkers PC3X and PRO-C3 as compared to COVID-19 patients who did not develop ILD. These data indicate that type III collagen formation is increased even further in COVID-19 patients who develop ILD compared to those without ILD at three months after discharge. These findings align with other studies which have shown elevated PRO-C3 levels at baseline in patients with a fibrotic subtype of ILD, idiopathic pulmonary fibrosis (IPF), as compared to controls [10]. Additionally, PRO-C3 has been shown to be prognostic for IPF progression within 12 months and has been associated with a higher mortality at three-year follow-up in IPF patients with high baseline levels compared to low [9, 56]. Further investigations are needed to assess the potential of these biomarkers as tools to identify COVID-19 patients with a high type III collagen formation profile at risk of developing ILD. Such studies could potentially identify patients suitable for more in-depth investigations and these biomarkers may have the potential to be used for patient stratification or monitoring in clinical trials. As these biomarkers measure systemic levels of type III collagen remodelling, they could originate from any tissue or organ in the body. It can be speculated, however, if the increased type III collagen remodelling originates from the lung, considering the additional increase in serum levels associated with patients who develop post-COVID ILD.

A limitation of this study was the non-matched groups of healthy controls and COVID-19. However, with the exception of PC3X, PRO-C6, and C6M, biomarkers did not seem to be influenced by age, gender, ethnicity, or comorbidities. The biomarkers that had confounding factors were adjusted accordingly and no differences were found, indicating that our data are reliable. As data were collected as part of clinical care, a formal scoring for the severity of ILD was not conducted. In future studies, it would be interesting to investigate whether there are associations between ECM biomarkers and severity of ILD. Additionally, due to limited sample size, the findings might only be indicative of the pathophysiological processes that occurs in COVID-19 and post-COVID ILD and further investigations in bigger cohorts are needed to validate these findings.

Conclusion

In this exploratory biomarker study, serological biomarkers were used to assess tissue remodelling, wound healing, and neutrophil activity in patients with COVID-19 and post-COVID ILD. Biomarkers of type III collagen remodelling, clot formation, and neutrophil activity were significantly elevated in COVID-19 compared to healthy controls, and type III collagen formation biomarkers were further elevated in patients with post-COVID ILD. These data align with previous findings and suggest that there is an increased neutrophil activity in patients with COVID-19 at three months after discharge, potentially leading to an excessive inflammatory response and subsequent lung tissue remodelling. Further investigations are needed to assess the potential of these biomarkers as tools to identify COVID-19 patients at high risk of developing ILD and to assist the development of new therapeutic approaches.

Data availability

No datasets were generated or analysed during the current study.

Abbreviations

ARDS:

Acute respiratory distress syndrome

COPD:

Chronic obstructive pulmonary disease

COVID-19:

Coronavirus disease 2019

CRP:

C-reactive protein

CT:

Computed tomography

CV:

Coefficient of variance

DLCO:

Diffusing capacity for carbon monoxide

ELISA:

Enzyme-linked immunosorbent assay

FVC:

Forced vital capacity

ILD:

Interstitial lung disease

IPF:

Idiopathic pulmonary fibrosis

IQR:

Inter quartile range

LLMR:

Lower limit measurement range

NET:

Neutrophil extracellular trap

SARS-CoV-2:

Severe acute respiratory syndrome coronavirus 2

SD:

Standard deviation

ULMR:

Upper limit measurement range

References

  1. Wang H, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet. 2022;399:1513.

    Article  CAS  Google Scholar 

  2. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181.

    Article  CAS  PubMed  Google Scholar 

  3. Gavriatopoulou M, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20:493.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Chen T et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, (2020).

  5. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Burgstaller G, et al. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. Eur Respir J. 2017;50:1601805.

    Article  PubMed  Google Scholar 

  7. Singh D, Rai V, Agrawal DK. Regulation of collagen I and Collagen III in tissue Injury and Regeneration. Cardiol Cardiovasc Med. 2023;7:5.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ito JT et al. Extracellular Matrix Component Remodeling in Respiratory diseases: what has been found in clinical and. Experimental Studies? Cells 8, (2019).

  9. Hoyer N, et al. High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosis. Respirology. 2021;26:582–9.

    Article  PubMed  Google Scholar 

  10. Organ LA, et al. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res. 2019;20:1–10.

    Article  CAS  Google Scholar 

  11. Jenkins RG, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med. 2015;3:462–72.

    Article  CAS  PubMed  Google Scholar 

  12. Gaggar A, Weathington N. Bioactive extracellular matrix fragments in lung health and disease. J Clin Invest. 2016;126:3176.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383:120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Schurink B, et al. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1:e290–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Spagnolo P, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8:750–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhao Y, miao et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 25, (2020).

  17. Wu X, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9:747–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Stewart I, et al. Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD Post–COVID-19 study. Am J Respir Crit Care Med. 2023;207:693–703.

    Article  PubMed  Google Scholar 

  19. Das KM, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27:342–9.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Zhang P et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res 8, (2020).

  21. Zuo Y et al. Neutrophil extracellular traps in COVID-19. JCI Insight 5, (2020).

  22. Wan S, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;92:797.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Liu J, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020;18:206.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ma A, et al. High levels of circulating IL-8 and Soluble IL-2R are Associated with prolonged illness in patients with severe COVID-19. Front Immunol. 2021;12:626235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Masso-Silva JA, et al. Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients: a case series and review of the literature. Clin Infect Dis. 2022;74:479–89.

    Article  CAS  PubMed  Google Scholar 

  26. Veras FP et al. SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology. J Exp Med 217, (2020).

  27. Viode A, et al. Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes. Sci Adv. 2024;10:5762.

    Article  Google Scholar 

  28. Barnes BJ et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med 217, (2020).

  29. Cesta MC, et al. Neutrophil activation and neutrophil extracellular traps (NETs) in COVID-19 ARDS and immunothrombosis. Eur J Immunol. 2023;53:2250010.

    Article  CAS  PubMed  Google Scholar 

  30. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Burke H et al. Research evaluation alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study. BMJ Open 11, (2021).

  33. Jensen C, et al. Cross-linked multimeric pro-peptides of type III collagen (PC3X) in Hepatocellular Carcinoma – A Biomarker that provides additional Prognostic Value in AFP positive patients. J Hepatocell Carcinoma. 2020;7:301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Nielsen MJ, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5:303.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Nedergaard A, et al. Type VI collagen turnover-related peptides—novel serological biomarkers of muscle mass and anabolic response to loading in young men. J Cachexia Sarcopenia Muscle. 2013;4:267.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Leeming DJ, et al. A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers. 2011;16:616–28.

    Article  CAS  PubMed  Google Scholar 

  37. Barascuk N, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem. 2010;43:899–904.

    Article  CAS  PubMed  Google Scholar 

  38. Veidal SS et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis–identification and validation of a novel biochemical marker assay. PLoS ONE 6, (2011).

  39. Mortensen JH, et al. A specific calprotectin neo-epitope [CPa9-HNE] in serum from inflammatory bowel Disease patients is Associated with Neutrophil Activity and Endoscopic Severity. J Crohns Colitis. 2022;16:1447–60.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Gudmann NS, et al. Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease. Biochem Biophys Res Commun. 2018;503:1284–90.

    Article  CAS  PubMed  Google Scholar 

  41. Manon-Jensen T et al. End-product of fibrinogen is elevated in emphysematous chronic obstructive pulmonary disease and is predictive of mortality in the ECLIPSE cohort. Respir Med 160, (2019).

  42. Sun S, et al. Serological Assessment of the quality of Wound Healing processes in Crohn’s Disease. J Gastrointest Liver Dis. 2019;28:175–82.

    Article  CAS  Google Scholar 

  43. Anka AU, et al. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021;93:93.

    Article  Google Scholar 

  44. Karsdal MA. Biochemistry of Collagens, Laminins and Elastin: structure, function and biomarkers. Academic; 2019.

  45. Ackermann M, et al. The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling. EBioMedicine. 2022;85:104296.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Brown EA, et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Rep. 2023;5:100661.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lehmann A et al. Impact of persistent D-dimer elevation following recovery from COVID-19. PLoS ONE 16, (2021).

  48. Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. https://doi.org/10.1080/17474086.2020.1831383 13, 1265–75 (2020).

  49. Polverino E, Rosales-Mayor E, Dale GE, Dembowsky K, Torres A. The role of neutrophil elastase inhibitors in Lung diseases. Chest. 2017;152:249–62.

    Article  PubMed  Google Scholar 

  50. Silvin A, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182:1401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Seren S et al. Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia. Eur Respir J 57, (2021).

  52. Guéant JL, et al. Elastase and exacerbation of neutrophil innate immunity are involved in multi-visceral manifestations of COVID-19. Allergy. 2021;76:1846–58.

    Article  PubMed  Google Scholar 

  53. Wang Z, et al. Plasma neutrophil elastase and Elafin Imbalance is Associated with Acute Respiratory Distress Syndrome (ARDS) Development. PLoS ONE. 2009;4:e4380.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hashimoto S, et al. Neutrophil elastase activity in acute lung injury and respiratory distress syndrome. Respirology. 2008;13:581–4.

    Article  PubMed  Google Scholar 

  55. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest. 2002;121:S151–5.

    Article  Google Scholar 

  56. Jessen H, et al. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respir Res. 2021;22:205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We wish to acknowledge all the people who has been involved in the work for this project. Additionally, we wish to acknowledge all the participants, medical-, nursing-, and technical-staff who has been involved in collecting the samples for this study. Lastly, we wish to acknowledge all the organizations who funded the study.

Funding

This study has been funded by the Danish Research Foundation and University Hospital Southampton Biomedical Research Centre.

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark

    Helene Wallem Breisnes

  2. Hepatic and Pulmonary Research, Nordic Bioscience, Herlev, Denmark

    Helene Wallem Breisnes, Diana Julie Leeming, Morten Asser Karsdal & Jannie Marie Bülow Sand

  3. NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, England

    Hannah Burke, Anna Freeman, Tom Wilkinson & Aishath Fazleen

  4. CES, Faculty of Medicine, University of Southampton, Southampton, Hampshire, England

    Tom Wilkinson & Aishath Fazleen

Authors
  1. Helene Wallem Breisnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Julie Leeming
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Morten Asser Karsdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hannah Burke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tom Wilkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aishath Fazleen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jannie Marie Bülow Sand
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: HWB, AFa, JMBS. Acquisition of data: HWB, HB, AFr, TW, AFa, JMBS. Analysis and interpretation of data: HWB, DJL, JMBS. Experimental support: DJL, JMBS. Drafting of the manuscript: HWB. Critical revision of the manuscript for important intellectual content: HWB, DJL, MAK, TW, AFa, JMBS. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Helene Wallem Breisnes.

Ethics declarations

Ethics approval and consent to participate

Patient samples were collected as part of the REACT study. This study was approved by London-Bromley Research Ethics Committee (REC) - Health Research Authority, REC reference 20/HRA/2986. Patient samples were collected under the Southampton Research Biorepository amendment and provided written consent. According to the qualified vendor BioIVT, healthy samples were collected in compliance with the REC recommendations.

Consent for publication

Not applicable.

Competing interests

D. J. Leeming, M. A. Karsdal, and J. M. B. Sand are employed at Nordic Bioscience which is a company involved in discovery and development of biochemical markers. Additionally, D. J. Leeming, M. A. Karsdal, and J. M. B. Sand are shareholders in Nordic Bioscience Holding A/S. H.W. Breisnes is a PhD student at University of Copenhagen, conducting her project in collaboration with Nordic Bioscience.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Breisnes, H.W., Leeming, D.J., Karsdal, M.A. et al. Biomarkers of tissue remodelling are elevated in serum of COVID-19 patients who develop interstitial lung disease - an exploratory biomarker study. BMC Pulm Med 24, 331 (2024). https://doi.org/10.1186/s12890-024-03144-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12890-024-03144-0

Keywords

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us